To assess the prevalence and clinical implications of DCLK1 expression in HNSCC, were analyzed DCLK1 protein levels by IHC in a tumor microarray (TMA) comprised of 273 cancer biopsies (233 patients presented with a primary tumors and 40 patients presented with recurrent malignancies) (Figure 6A). The gene discussed is DCLK1; the disease is neoplasm.